NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$45.96

-0.33 (-0.71 %)

(As of 01/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$45.23

Now: $45.96▼

$47.81

50-Day Range

$46.29

MA: $51.17▼

$54.26

52-Week Range

$14.16

Now: $45.96▼

$55.22

Volume275,465 shs

Average Volume216,105 shs

Market Capitalization$1.86 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.36

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

MarketRank^™

Overall MarketRank^™

1.81 out of 5 stars

Medical Sector

138th out of 1,928 stocks

Pharmaceutical Preparations Industry

66th out of 774 stocks

4.4 Analyst's Opinion

Consensus Rating
Y-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $58.33, Y-mAbs Therapeutics has a forecasted upside of 26.9% from its current price of $45.96.
Amount of Analyst Coverage
Y-mAbs Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.4 Community Rank

Outperform Votes
Y-mAbs Therapeutics has received 85 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Y-mAbs Therapeutics has received 92 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Y-mAbs Therapeutics has received 51.98% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote “Outperform” if you believe YMAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Y-mAbs Therapeutics does not currently pay a dividend.
Dividend Growth
Y-mAbs Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Y-mAbs Therapeutics insiders have sold 8,012.14% more of their company's stock than they have bought. Specifically, they have bought $78,853.00 in company stock and sold $6,396,662.00 in company stock.
Percentage Held by Insiders
38.40% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.20% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($3.25) to ($1.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Y-mAbs Therapeutics is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Y-mAbs Therapeutics is -15.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Y-mAbs Therapeutics has a P/B Ratio of 9.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:YMAB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.ymabs.com

Phone646-885-8505

Employees65

Debt

Debt-to-Equity RatioN/A

Current Ratio10.40

Quick Ratio10.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.01 per share

Price / Book9.17

Profitability

EPS (Most Recent Fiscal Year)($2.30)

Net Income$-81,030,000.00

Net MarginsN/A

Return on Equity-74.98%

Return on Assets-66.70%

Miscellaneous

Outstanding Shares40,514,000

Market Cap$1.86 billion

Next Earnings Date3/11/2021 (Estimated)

OptionableNot Optionable

$45.96

-0.33 (-0.71 %)

(As of 01/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

How has Y-mAbs Therapeutics' stock been impacted by COVID-19?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, YMAB shares have increased by 100.0% and is now trading at $45.96.
View which stocks have been most impacted by COVID-19.

Is Y-mAbs Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Y-mAbs Therapeutics?

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Y-mAbs Therapeutics' CEO?

1,428 employees have rated Y-mAbs Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Y-mAbs Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Y-mAbs Therapeutics.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.80) by $0.02.
View Y-mAbs Therapeutics' earnings history.

What price target have analysts set for YMAB?

8 analysts have issued 12-month price objectives for Y-mAbs Therapeutics' shares. Their forecasts range from $45.00 to $71.00. On average, they anticipate Y-mAbs Therapeutics' share price to reach $58.33 in the next year. This suggests a possible upside of 26.9% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Y-mAbs Therapeutics' key competitors?

Some companies that are related to Y-mAbs Therapeutics include Galapagos (GLPG), Allakos (ALLK), Schrödinger (SDGR), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Blueprint Medicines (BPMC), Evotec (EVTCY), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Maravai LifeSciences (MRVI), Eidos Therapeutics (EIDX), Atea Pharmaceuticals (AVIR), Sage Therapeutics (SAGE) and Arena Pharmaceuticals (ARNA).
View all of YMAB's competitors.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:

Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. and Strategy (Age 50, Pay $766.75k)
Dr. Claus Juan MÃ¸ller San Pedro M.D., Ph.D., CEO & Director (Age 58, Pay $967.5k)
Mr. Bo Kruse, Exec. VP, Sec., Treasurer & CFO (Age 48, Pay $608.35k)
Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 46)
Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 69)
Dr. Steen Lisby M.D., M.Sc., Sr. VP & Chief Scientific Officer (Age 56)
Mr. Philip Herman, Sr. VP & Chief Commercial Officer (Age 41)
Dr. Vignesh Rajah, Sr. VP & Chief Medical Officer

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include DNB Asset Management AS (0.06%). Company insiders that own Y-mAbs Therapeutics stock include Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics.

Which major investors are buying Y-mAbs Therapeutics stock?

YMAB stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics or or view top insider-buying stocks.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $45.96.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $1.86 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Y-mAbs Therapeutics employs 65 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here